Page results
-
Our outpatient clinics will remain predominantly virtual throughout the COVID-19 pandemic. Please continue to refer via the NHS e-referral service.
-
This page provides information about the WEB device and how it is used to treat cerebral (brain) aneurysms
-
UCLH has recruited the first European participant to a trial looking at treating non-hospitalised Covid-19 patients with the drug remdesivir.
-
This page tells you about the procedure known as a Bronchial Artery Embolisation (BAE).
-
The world’s first COVID-19 vaccine study researching alternating doses and intervals of approved vaccines is taking place at UCLH.
-
Lizzi Jordan, who received life-saving treatment at UCLH before going on to win a gold medal for cycling in the 2024 Paralympic Games, paid tribute to UCLH staff as she was made a Member of the British Empire (MBE).
-
In a major study involving UCLH a third of people who took a new drug for treating obesity lost more than one-fifth of their total body weight.
-
SUMMIT Study results on the benefits of large-scale screening for lung cancer are published in The Lancet Oncology today (26 March), ahead of the formal addition of lung cancer screening to the UK national screening programme from 1 April.
-
A front page story and patient case study highlight SUMMIT Study early diagnosis outcomes.
-
Dr Patrick Murphy is a consultant clinical neuropsychologist at the National Hospital for Neurology and Neurosurgery.
File results
-
FOI/2022/0550 - Patients that have been treated for glioblastoma brain cancer
-
FOI/2022/0553 - Patients tested for non-small cell lung cancer biomarkers
-
FOI/2022/0561 - Regulation (EU) 2016/425 Declarations of Conformity for all type IIR surgical masks provided as PPE to staff
-
FOI/2022/0571 - Treatment for biologic medicines in Dermatology
-
FOI/2022/0572 - Treatments for Hidradenitis Suppurativa and Psoriasis
-
FOI/2022/0573 - Use of WhatsApp by or within the Trust
-
FOI/2022/0513 - Myelofibrosis treatment
-
FOI/2022/0540 - Electronic patient record
-
FOI/2022/0541 - Serious Incidents Level 2 deaths/ serious harm
-
FOI/2022/0576 - Medications within dermatology